

HR 3282

Promoting Transparency and Healthy Competition in Medicare Act

Congress: 118 (2023–2025, Ended)

Chamber: House

Policy Area: Health

Introduced: May 15, 2023

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Dec 17, 2024)

Official Text: <https://www.congress.gov/bill/118th-congress/house-bill/3282>

Sponsor

Name: Rep. Harshbarger, Diana [R-TN-1]

Party: Republican • State: TN • Chamber: House

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bilirakis, Gus M. [R-FL-12]	R · FL		May 15, 2023
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		May 15, 2023
Rep. Schrier, Kim [D-WA-8]	D · WA		May 15, 2023

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	May 19, 2023
Ways and Means Committee	House	Referred to	Dec 17, 2024

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 HR 3561	Related bill	Dec 17, 2024: Referred to the Subcommittee on Health.

## Promoting Transparency and Healthy Competition in Medicare Act

This bill requires Medicare Advantage (MA) organizations and prescription drug plan (PDP) sponsors and pharmacy benefit managers (PBMs) under the Medicare prescription drug benefit to report certain information relating to their ownership interests in participating providers.

Specifically, MA organizations must report on items and services, patient risk scores and associated diagnoses, prior authorization requests, and incentive payments with respect to providers in which the MA organization has an ownership interest as compared to other providers.

Similarly, PDP sponsors under the Medicare prescription drug benefit must report on the prices of prescription drugs with respect to pharmacies in which the PDP sponsor has an ownership interest as compared to other pharmacies. The bill also prohibits PDP sponsors from contracting with PBMs in which the PDP sponsor has an ownership interest unless the PBM reports certain information on rebates and payments between the PBM, PDP sponsor, pharmacies, and drug manufacturers.

## Actions Timeline

---

- **Dec 17, 2024:** Referred to the Subcommittee on Health.
- **May 19, 2023:** Referred to the Subcommittee on Health.
- **May 15, 2023:** Introduced in House
- **May 15, 2023:** Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.